BACKGROUND AND OBJECTIVES: Although early studies suggest that patients with idiopathic membranous nephropathy (MGN) and subnephrotic range proteinuria overall do well, these studies were small and follow-up was short or difficult to discern. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Three hundred ninety-five cases of idiopathic MGN with at least 12 mo of follow-up from the Toronto Glomerulonephritis Registry were reviewed to determine the outcome of the subgroup of patients that presented with subnephrotic range proteinuria. Onset and follow-up data included mean arterial pressure (MAP) and creatinine clearance (CrCl) as determined by the Cockcroft-Gault equation. Outcome variables included the rate of progression (slope of CrCl), 50% reduction in initial CrCl, and end-stage renal disease (ESRD). RESULTS: One hundred eight (27% of the total) patients presented with subnephrotic proteinuria and almost 40% (42 of 108) of this subgroup remained subnephrotic. Their long-term slope was -0.93 ml/min/yr. In contrast, those who subsequently developed nephrotic range proteinuria had a progression rate almost four times faster (-3.52 ml/min/yr). The majority who developed nephrotic syndrome did so within the first year of follow-up. The only distinguishing baseline feature between the two groups was a higher level of urine protein in the group that subsequently developed nephrotic syndrome (1.98 [0.3 to 3.4] versus 2.43 [0.5 to 3.4] g/d). CONCLUSIONS: Patients with MGN and sustained subnephrotic range proteinuria have an excellent prognosis. Conservative management with close monitoring is recommended given the difficulty predicting which patients will develop nephrotic range proteinuria and then progress more rapidly.
BACKGROUND AND OBJECTIVES: Although early studies suggest that patients with idiopathic membranous nephropathy (MGN) and subnephrotic range proteinuria overall do well, these studies were small and follow-up was short or difficult to discern. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Three hundred ninety-five cases of idiopathic MGN with at least 12 mo of follow-up from the Toronto Glomerulonephritis Registry were reviewed to determine the outcome of the subgroup of patients that presented with subnephrotic range proteinuria. Onset and follow-up data included mean arterial pressure (MAP) and creatinine clearance (CrCl) as determined by the Cockcroft-Gault equation. Outcome variables included the rate of progression (slope of CrCl), 50% reduction in initial CrCl, and end-stage renal disease (ESRD). RESULTS: One hundred eight (27% of the total) patients presented with subnephrotic proteinuria and almost 40% (42 of 108) of this subgroup remained subnephrotic. Their long-term slope was -0.93 ml/min/yr. In contrast, those who subsequently developed nephrotic range proteinuria had a progression rate almost four times faster (-3.52 ml/min/yr). The majority who developed nephrotic syndrome did so within the first year of follow-up. The only distinguishing baseline feature between the two groups was a higher level of urine protein in the group that subsequently developed nephrotic syndrome (1.98 [0.3 to 3.4] versus 2.43 [0.5 to 3.4] g/d). CONCLUSIONS:Patients with MGN and sustained subnephrotic range proteinuria have an excellent prognosis. Conservative management with close monitoring is recommended given the difficulty predicting which patients will develop nephrotic range proteinuria and then progress more rapidly.
Authors: Loreto Gesualdo; Anna Maria Di Palma; Luigi Francesco Morrone; Giovanni Fabrizio Strippoli; Francesco Paolo Schena Journal: Kidney Int Date: 2004-09 Impact factor: 10.612
Authors: Stéphan Troyanov; Catherine A Wall; Judith A Miller; James W Scholey; Daniel C Cattran Journal: Kidney Int Date: 2004-09 Impact factor: 10.612
Authors: Daniel C Cattran; Heather N Reich; Heather J Beanlands; Judith A Miller; James W Scholey; Stéphan Troyanov Journal: Nephrol Dial Transplant Date: 2008-01-08 Impact factor: 5.992
Authors: Natalia Polanco; Elena Gutiérrez; Adelardo Covarsí; Francisco Ariza; Agustín Carreño; Ana Vigil; José Baltar; Gema Fernández-Fresnedo; Carmen Martín; Salvador Pons; Dolores Lorenzo; Carmen Bernis; Pilar Arrizabalaga; Gema Fernández-Juárez; Vicente Barrio; Milagros Sierra; Ines Castellanos; Mario Espinosa; Francisco Rivera; Aniana Oliet; Francisco Fernández-Vega; Manuel Praga Journal: J Am Soc Nephrol Date: 2010-01-28 Impact factor: 10.121
Authors: Paul Perco; Wenjun Ju; Julia Kerschbaum; Johannes Leierer; Rajasree Menon; Catherine Zhu; Matthias Kretzler; Gert Mayer; Michael Rudnicki Journal: JCI Insight Date: 2019-06-20
Authors: Daniel C Cattran; Esther D Kim; Heather Reich; Michelle Hladunewich; S Joseph Kim Journal: J Am Soc Nephrol Date: 2016-10-18 Impact factor: 10.121
Authors: Sean J Barbour; Daniel C Cattran; Gabriela Espino-Hernandez; Michelle A Hladunewich; Heather N Reich Journal: Kidney Int Date: 2015-08-19 Impact factor: 10.612